Integrated Behavioral Intervention for Cigarette Smoking and Binge Drinking in Young Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Nicotine patches and behavioral therapy may help reduce cigarette smoking and binge drinking in young adults. PURPOSE: This randomized clinical trial studies nicotine patches with or without behavioral therapy in reducing cigarette smoking and binge drinking in young adults.
| Condition | Intervention |
|---|---|
|
for Cigarette Smoking and Binge Drinking Cessation |
Drug: nicotine transdermal patch Behavioral: behavioral intervention |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Integrated Intervention for Cigarette Smoking and Binge Drinking for Young Adults |
- Biochemically-confirmed 7-day point prevalence tobacco abstinence [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
- Effect of the integrated intervention on binge drinking [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
- Possible mediators of the intervention [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
| Enrollment: | 170 |
| Study Start Date: | August 2010 |
| Study Completion Date: | February 2013 |
| Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I
Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
|
Drug: nicotine transdermal patch
21mg for 4 weeks, 14mg for 2 weeks, and 7mg for 2 weeks
Other Name: nicotine transdermal system patch
Behavioral: behavioral intervention
8 session behavioral intervention.
Other Names:
|
|
Experimental: Arm II
Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
|
Drug: nicotine transdermal patch
21mg for 4 weeks, 14mg for 2 weeks, and 7mg for 2 weeks
Other Name: nicotine transdermal system patch
Behavioral: behavioral intervention
8 session behavioral intervention.
Other Names:
|
Detailed Description:
OBJECTIVES: I. To evaluate the efficacy of Integrated Intervention that targets both cigarette smoking and binge drinking on the cigarette smoking behavior of young adult smokers at 6-month follow-up. II. To evaluate the efficacy of Integrated Intervention that targets both cigarette smoking and binge drinking on binge drinking behavior of young adult smokers. III. Examine the effect of Integrated Intervention on several possible mediators of change corresponding to mechanisms that have been proposed to account for the relationship between cigarette smoking and alcohol use. These mediators include cravings to smoke, perceived similarity to the typical smoker, and self-efficacy for smoking abstinence. OUTLINE: Patients are randomized to 1 of 2 treatment arms.All patients receive nicotine patch therapy in weeks 4-11. ARM I: Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6. ARM II: Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.After completion of study treatment, patients are followed up at weeks 12, 16, 20, and 24.
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: - Smoked an average of >= 10 or more cigarettes per day during the past 6 months - Binge drank on an average of >= 2 occasions per month during the past 3 months - Able to participate fully in all aspects of the intervention and keep all scheduled appointments - Willing to participate in 6 months of follow-up - Willing to stop smoking and use nicotine patch therapy - Willing to refrain from participating in additional smoking interventions for the duration of the study - Provide written informed consent Exclusion Criteria: - Current (past 90 days) alcohol dependence as assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders, Alcohol Dependence Module - Current (past 12 months) non-nicotine or alcohol drug dependence as assessed by a Drug Abuse Screening Test-20 score of >= 6 - Current elevation of depressive symptoms (past 2 weeks) that would be indicative of clinical depression as assessed by a Beck Depression Inventory-II score of >= 20 - Current use (past 30 days) of nicotine containing medication or frequent use (> 10 occasions per month) of tobacco products other than cigarettes - Current use (past 30 days) of any other smoking cessation treatment involving behavioral or pharmacological interventions - Any medical condition that would preclude use of the nicotine patch including current unstable angina, recent history (past 30 days) of myocardial infarction or stroke, history of severe skin allergies, or evidence of severe chronic dermatosis - Currently pregnant or breast feeding, or likely to become pregnant during the nicotine patch phase
Contacts and Locations| United States, Florida | |
| Mayo Clinic | |
| Jacksonville, Florida, United States | |
| Principal Investigator: | Steven Ames | Mayo Clinic |
More Information
No publications provided
| Responsible Party: | Steven Ames, MD, Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01184261 History of Changes |
| Other Study ID Numbers: | 10-000432, NCI-2010-01881 |
| Study First Received: | August 17, 2010 |
| Last Updated: | May 8, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Smoking Binge-Eating Disorder Habits Eating Disorders Mental Disorders Nicotine Nicotine polacrilex Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Pharmacologic Actions Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013